Blue Owl Capital Holdings LP 13F Holdings · Q2 2026
Blue Owl Capital Holdings LP reported 71 securities worth $664.51M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: SPCX (35.97%), AKTS (14.89%), CGEM (4.22%). Among its top 25 positions this quarter: 6 new, 7 added, 8 trimmed.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | SPCX | SPACE EXPLORATION TECHN CORP | $239.0M | 35.97% | 1.4M | New |
| 2 | AKTS | AKTIS ONCOLOGY INC | $99.0M | 14.89% | 3.1M | Trimmed |
| 3 | CGEM | CULLINAN THERAPEUTICS INC | $28.0M | 4.22% | 1.5M | Trimmed |
| 4 | LRMR | LARIMAR THERAPEUTICS INC | $27.9M | 4.21% | 9.2M | Added |
| 5 | NCDL | NUVEEN CHURCHILL DIRECT LEND | $26.6M | 4.01% | 2.1M | Hold |
| 6 | MPLT | MAPLIGHT THERAPEUTICS INC | $26.2M | 3.94% | 729,929 | Trimmed |
| 7 | COF | CAPITAL ONE FINL CORP | $24.0M | 3.62% | 119,757 | New |
| 8 | OBDC | BLUE OWL CAPITAL CORPORATION | $22.2M | 3.35% | 2.0M | Hold |
| 9 | FISN | DEEP FISSION INC | $14.7M | 2.22% | 1.3M | New |
| 10 | DELL | DELL TECHNOLOGIES INC | $14.2M | 2.14% | 32,961 | Added |
| 11 | HLLY | HOLLEY INC | $11.2M | 1.68% | 4.4M | Added |
| 12 | EYPT | EYEPOINT INC | $10.9M | 1.64% | 762,594 | Trimmed |
| 13 | SGMT | SAGIMET BIOSCIENCES INC | $9.7M | 1.47% | 1.3M | Added |
| 14 | CRVS | CORVUS PHARMACEUTICALS INC | $9.1M | 1.37% | 608,600 | Added |
| 15 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $8.5M | 1.28% | 874,542 | New |
| 16 | CMPX | COMPASS THERAPEUTICS INC | $7.9M | 1.19% | 3.6M | Added |
| 17 | CNDT | CONDUENT INC | $7.4M | 1.11% | 5.0M | Hold |
| 18 | RYTM | RHYTHM PHARMACEUTICALS INC | $6.8M | 1.03% | 61,455 | Hold |
| 19 | CMPS | COMPASS PATHWAYS PLC | $6.4M | 0.96% | 450,000 | New |
| 20 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $6.1M | 0.92% | 182,638 | Trimmed |
| 21 | PVLA | PALVELLA THERAPEUTICS INC NE | $5.5M | 0.83% | 36,259 | Added |
| 22 | IMA | IMAGENEBIO INC | $5.4M | 0.81% | 917,692 | Trimmed |
| 23 | CMPS | COMPASS PATHWAYS PLC | $5.2M | 0.78% | 1.7M | Trimmed |
| 24 | VRDN | VIRIDIAN THERAPEUTICS INC | $4.8M | 0.72% | 260,000 | New |
| 25 | IMMX | IMMIX BIOPHARMA INC | $4.5M | 0.68% | 437,552 | Trimmed |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR